NCT02551042View on ClinicalTrials.gov

CSL Behring Sclero XIII

PHASE2UnknownINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2018

Conditions

Systemic Sclerosis

Interventions

DRUG

Fibrogammin®P, coagulation factor XIII concentrate (Human)

IV infusion

DRUG

0.9% sodium chloride

IV infusion

Trial Locations (1)

NW3 2QG

RECRUITING

Royal Free London NHS Foundation Trust, London

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

CSL Behring

INDUSTRY

lead

University College, London

OTHER